ChengDa Pharmaceuticals Co., Ltd.

301201

CNE100005766

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-14 pm EDT			5-day change	1st Jan Change
18.22 ^CNY	-2.62%		+2.19%	-28.35%

Jul. 03	ChengDa Pharmaceuticals Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 10 July 2024	CI
Jul. 02	Tranche Update on ChengDa Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on January 9, 2024.	CI

Tranche Update on ChengDa Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on January 9, 2024.

July 02, 2024 at 05:32 am EDT

From April 1, 2024 to June 30, 2024, the company has repurchased 190,700 shares, representing 0.13% for CNY 3.35 million. With this, the company has completed the repurchase of 3,137,500 shares, representing 2.03% for CNY 55.27 million under the buyback announced on January 9, 2024.

Latest news about ChengDa Pharmaceuticals Co., Ltd.

ChengDa Pharmaceuticals Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 10 July 2024	Jul. 03	CI
Tranche Update on ChengDa Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on January 9, 2024.	Jul. 02	CI
ChengDa Pharmaceuticals Co., Ltd.(XSEC:301201) dropped from S&P Global BMI Index	Jun. 23	CI
ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2023	May. 14	CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 21	CI
Tranche Update on ChengDa Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on January 9, 2024.	Apr. 01	CI
Certain A Shares of ChengDa Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	Jan. 19	CI
ChengDa Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	Jan. 09	CI
ChengDa Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.	Jan. 08	CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
ChengDa Pharmaceuticals Co., Ltd.(XSEC:301201) added to S&P Global BMI Index	23-09-17	CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023	23-07-03	CI
Chengda Pharmaceuticals Co., Ltd. Announces Directorate Appointments	23-05-17	CI
Chengda Pharmaceuticals Co., Ltd. Approves for the Year 2022	23-05-17	CI
Chengda Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2022	23-04-24	CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-23	CI
Certain A Shares of ChengDa Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-JAN-2023.	23-01-19	CI
One Gene announced that it has received funding from ChengDa Pharmaceuticals Co., Ltd.	22-12-07	CI
Hangzhou 1gene Technology Co., Ltd. announced that it has received CNY 19.48156 million in funding from ChengDa Pharmaceuticals Co., Ltd.	22-12-07	CI
Hangzhou 1gene Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from ChengDa Pharmaceuticals Co., Ltd.	22-11-06	CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-14	CI
ChengDa Pharmaceuticals to Free Up 1.29% Stake For Trading	22-07-17	MT
ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022	22-05-23	CI

Chart ChengDa Pharmaceuticals Co., Ltd.

Duration

Period

More charts

Company Profile

Chengda Pharmaceuticals Co Ltd is a China-based company mainly engaged in customized R&D and production of pharmaceutical intermediates. The Company is also engaged in the production and sales of L-carnitine series products and active pharmaceutical ingredients (APIs). The pharmaceutical intermediate products include NP0805/NP0908, NP1205, NP0806, NP1011/1214, NP1709 and others. The L-carnitine series products are used in the fields of food additives, feed additives and raw materials. The APIs products include Buwaxitan, Vidagliptin, Elagoli and others. The Company's products are exported to the United States, Europe, Japan, Canada, the United Kingdom, Italy and other countries and regions.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHENGDA PHARMACEUTICALS CO., LTD.	-28.35%	392M
ELI LILLY AND COMPANY	+63.05%	854B
NOVO NORDISK A/S	+39.42%	636B
JOHNSON & JOHNSON	-4.78%	361B
MERCK & CO., INC.	+17.52%	324B
ABBVIE INC.	+8.43%	301B
ASTRAZENECA PLC	+14.19%	247B
ROCHE HOLDING AG	+5.81%	230B
NOVARTIS AG	+16.77%	228B
AMGEN INC.	+14.63%	177B